Form 8-K
8-K — ZIMMER BIOMET HOLDINGS, INC.
Accession: 0001193125-26-385256
Filed: 2026-09-08
Period: 2026-09-08
CIK: 0001136869
SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — d304716d8k.htm (Primary)
EX-99.1 (d304716dex991.htm)
GRAPHIC (g304716g0908230230083.jpg)
GRAPHIC (g304716g14a91.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d304716d8k.htm · Sequence: 1
8-K
false 0001136869 0001136869 2026-09-08 2026-09-08 0001136869 us-gaap:CommonStockMember 2026-09-08 2026-09-08 0001136869 zbh:M2.425NotesDue2026Member 2026-09-08 2026-09-08 0001136869 zbh:M1.164NotesDue2027Member 2026-09-08 2026-09-08 0001136869 zbh:M3.518NotesDue2032Member 2026-09-08 2026-09-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2026
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-16407
13-4151777
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
345 East Main Street
Warsaw, Indiana
46580
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (574) 373-3333
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.01 par value
ZBH
New York Stock Exchange
2.425% Notes due 2026
ZBH 26
New York Stock Exchange
1.164% Notes due 2027
ZBH 27
New York Stock Exchange
3.518% Notes due 2032
ZBH 32
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured. Mr. Thornal will be departing from the Company, effective on September 30, 2026.
Mr. Thornal will be eligible for severance benefits under the Company’s Restated Executive Severance Plan, as amended (the “Severance Plan”). Pursuant to the Severance Plan, Mr. Thornal will receive benefits, including a lump sum amount equal to the sum of twelve months of his annual base salary plus target annual bonus, plus twelve months of his current monthly COBRA premiums. His right to receive such severance payments and benefits is conditioned upon his executing and not revoking a general release in favor of the Company. A summary of the Severance Plan is included in the Company’s definitive proxy statement filed on April 1, 2026 under “Executive Compensation – Potential Payments upon Termination of Employment – Executive Severance Plan.” The Severance Plan was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 6, 2018, and the Amendment to the Severance Plan was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 5, 2022.
Item 7.01
Regulation FD Disclosure.
On September 8, 2026, the Company issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated September 8, 2026
101
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH
Inline XBRL Taxonomy Extension Schema Document
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 8, 2026
ZIMMER BIOMET HOLDINGS, INC.
By:
/s/ Chad F. Phipps
Name:
Chad F. Phipps
Title:
Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary
3
EX-99.1
EX-99.1
Filename: d304716dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Gary Campbell promoted to President, Americas
Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery
Bradley Kessler promoted to President, Americas – Robotics, Technology and Data
(WARSAW, Ind.) September 8, 2026 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today
announced leadership appointments designed to streamline its Americas and Global Business Group organizations for greater focus and agility.
Effective
October 1, Gary Campbell will be promoted to President, Americas, and Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery. The company also announced the promotion of Bradley Kessler to President, Americas
– Robotics, Technology and Data. Campbell, Hatcher and Kessler will report directly to Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.
“We talk often about our People and Culture strategic imperative to have the right talent, in the right roles, at the right times,” said Tornos.
“These well-deserved promotions do exactly that, while helping to accelerate our U.S. go-to-market transformation and sharpen ownership of our most important
commercial priorities. Gary, Brian and Brad are seasoned operators and proven Zimmer Biomet leaders with deep experience in the businesses and markets they will now lead. Their promotions reinforce my strong confidence in both our 2026 outlook and
our growth potential in 2027 and beyond.”
As part of this restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will
leave the company on September 30, 2026, following a transition period.
Tornos added, “On behalf of the entire Zimmer Biomet team, I want to
thank Kevin for his leadership and contributions to our company. We wish him all the best in his next chapter.”
2026 Outlook
Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026.
About Gary Campbell
As President, Americas, Campbell
will be responsible for commercial strategy and execution across the United States, Canada and Latin America. He will continue to lead the evolution of the company’s U.S.
go-to-market model, building a specialized and dedicated organization designed to increase productivity and accelerate growth.
Campbell has served as Zimmer Biomet’s vice president and general manager, Orthopedics – North
America since September 2024. Since joining the company in 2019, Campbell has held multiple commercial leadership roles of increasing responsibility. Previously, Campbell served in several sales and marketing roles at Enovis. He holds a
bachelor’s degree from Texas State University.
About Brian Hatcher
As President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead global portfolio strategy and execution across most of the company’s
businesses, expanding his current remit to include Global Knees and Hips. He will continue to play an integral role in the company’s innovation and diversification strategy, including delivering organic and inorganic opportunities in higher
growth markets. Lou Galrao, President of Reconstruction (Knees and Hips), will report to Hatcher.
During his
16-year career with Zimmer Biomet, Hatcher has held multiple roles in research, marketing, general management and business leadership. He was named to his first Global President role in 2021 and currently
serves as Zimmer Biomet’s President of S.E.T. and CMFT. Hatcher began his medical technology career with roles at OrbusNeich and later Medtronic. He holds a bachelor’s degree in chemistry and a Ph.D. in biomedical engineering, both from
the University of Florida.
About Brad Kessler
As
President, Americas – Robotics, Technology and Data, Kessler will be responsible for driving commercial strategy, growth and adoption of the company’s broad portfolio of robotics, digital and technology solutions in the Americas, as well
as its global service and capital solutions contracting business. Under Kessler’s leadership, the company will accelerate the expansion of its specialized robotics salesforce in advance of the highly anticipated launch of the Monogram
next-generation orthopedic robot, which is expected in 2027.
Kessler brings to the role more than two decades of commercial experience in orthopedics.
Currently vice president and general manager, Robotics, Technology and Data Solutions, Kessler has held multiple commercial leadership roles of increasing responsibility since he joined Zimmer Biomet in 2015. Prior to joining Zimmer Biomet, Kessler
spent nearly 10 years in sales at Stryker. He holds a bachelor’s degree from Texas A&M University and an Executive MBA from the Cox School of Business at Southern Methodist University.
# # #
2
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We
seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and
providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our
product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X
at www.x.com/zimmerbiomet.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, outlook, prospects, and product and service offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a
list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (“SEC”). These factors should not be construed as exhaustive and should be
read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that
these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
Contacts:
Media
Troy Kirkpatrick
614-284-1926
troy.kirkpatrick@zimmerbiomet.com
Kirsten Fallon
781-779-5561
kirsten.fallon@zimmerbiomet.com
Investors
David DeMartino
646-531-6115
david.demartino@zimmerbiomet.com
Zach Weiner
908-591-6955
zach.weiner@zimmerbiomet.com
3
GRAPHIC
GRAPHIC
Filename: g304716g0908230230083.jpg · Sequence: 7
Binary file (5559 bytes)
Download g304716g0908230230083.jpg
GRAPHIC
GRAPHIC
Filename: g304716g14a91.jpg · Sequence: 8
Binary file (6273 bytes)
Download g304716g14a91.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 10
v3.26.1
Document and Entity Information
Sep. 08, 2026
Document And Entity Information [Line Items]
Amendment Flag
false
Entity Central Index Key
0001136869
Document Type
8-K
Document Period End Date
Sep. 08, 2026
Entity Registrant Name
ZIMMER BIOMET HOLDINGS, INC.
Entity Incorporation State Country Code
DE
Entity File Number
001-16407
Entity Tax Identification Number
13-4151777
Entity Address, Address Line One
345 East Main Street
Entity Address, City or Town
Warsaw
Entity Address, State or Province
IN
Entity Address, Postal Zip Code
46580
City Area Code
(574)
Local Phone Number
373-3333
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title
Common Stock, $0.01 par value
Trading Symbol
ZBH
Security Exchange Name
NYSE
M 2.425 Notes Due 2026 [Member]
Document And Entity Information [Line Items]
Security 12b Title
2.425% Notes due 2026
Trading Symbol
ZBH 26
Security Exchange Name
NYSE
M 1.164 Notes Due 2027 [Member]
Document And Entity Information [Line Items]
Security 12b Title
1.164% Notes due 2027
Trading Symbol
ZBH 27
Security Exchange Name
NYSE
M 3.518 Notes Due 2032 [Member]
Document And Entity Information [Line Items]
Security 12b Title
3.518% Notes due 2032
Trading Symbol
ZBH 32
Security Exchange Name
NYSE
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- References
No definition available.
+ Details
Name:
zbh_DocumentAndEntityInformationLineItems
Namespace Prefix:
zbh_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=zbh_M2.425NotesDue2026Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=zbh_M1.164NotesDue2027Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=zbh_M3.518NotesDue2032Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: